Abstract
Introduction: After solid organ transplantation, patients require lifelong immunosuppressive medication, increasing susceptibility to COVID-19. We evaluated the clinical outcomes of heart transplant recipients in patients with COVID-19.
Methods: We enrolled twenty-two COVID-19 cases of adult heart transplantation from February 2020 to September 2021.
Results: The most common symptoms in patients were fever and myalgia. The death occurred in 3 (13.6 %).
Conclusion: Although heart transplantation mortality may increase in the acute rejection phase concomitant with COVID-19, immunosuppressive dose reduction may not be necessary for all heart transplant patients with COVID-19.